Prevents deep vein thrombosis (DVT). ANDA 206918, held by Eugia Pharma. Fondaparinux Sodium.
As of Nov 16, 2026, ANDA 206918 (Fondaparinux Sodium), held by Eugia Pharma, was first approved by FDA on Dec 26, 2017, with 0 approved supplements and 0 published complete response letters.
Fondaparinux sodium injection is a Factor Xa inhibitor (anticoagulant) indicated for: Prophylaxis of deep vein thrombosis (DVT) in patients undergoing hip fracture surgery (including extended prophylaxis), hip replacement surgery, knee replacement surgery, or abdominal surgery. Treatment of DVT or acute pulmonary embolism (PE) when administered in conjunction with warfarin. (1.2, 1.3) 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 26, 2017 | Original application | Approved |
| Fondaparinux Sodium2.5MG/0.5ML (2.5MG/0.5ML) · solution;subcutaneous | Fondaparinux Sodium | Rx |
| Fondaparinux Sodium5MG/0.4ML (5MG/0.4ML) · solution;subcutaneous | Fondaparinux Sodium | Rx |
| Fondaparinux Sodium7.5MG/0.6ML (7.5MG/0.6ML) · solution;subcutaneous | Fondaparinux Sodium | Rx |
| Fondaparinux Sodium10MG/0.8ML (10MG/0.8ML) · solution;subcutaneous | Fondaparinux Sodium | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters